Cancer News and Research

Latest Cancer News and Research

Endocrine Society honors BUSM professor with The Delbert A. Fisher Research Scholar Award

Michael F. Holick, PhD, MD, director of the General Clinical Research Center and professor of medicine, physiology and biophysics at Boston University School of Medicine, is this year's recipient of The Delbert A. Fisher Research Scholar Award from the Endocrine Society for his scholarly work on the history of endocrinology.

18 Jun 2011

Tobacco promotion banned in Queensland stores

Queensland stores are directed to refrain from openly displaying cigarettes and other tobacco products. Under laws introduced on Thursday, all retail advertising and promotion of tobacco and other smoking-related products will be banned.

17 Jun 2011

Adolescent obese males at risk of cancer later in life: Study

According to a new study, men who are obese as teenagers are at a greater risk of cancer. Researchers claim that the risk remains even among those who lose weight later in life.

17 Jun 2011

Cancer vaccine shows promise

In the latest research news, a cervical cancer vaccine programme has produced the first evidence of disease prevention among treated women. This vaccine targets human papillomavirus (HPV), the virus believed to trigger cervical cancer in women.

17 Jun 2011

RHEI receives Chinese SFDA acceptance letter for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.

17 Jun 2011

Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials.

17 Jun 2011

NASDAQ halts Regeneron's common stock

Regeneron Pharmaceuticals, Inc. announced that NASDAQ has halted trading of the company's common stock.

17 Jun 2011

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Celgene International Sarl today announced a collaboration to conduct an international randomized study to evaluate the therapeutic potential of the REVLIMID/rituximab combination regimen (R2) in patients with newly diagnosed follicular lymphoma.

17 Jun 2011

Precisely mapped allosteric binding site will facilitate design of drugs with minimal side effects

Structural biologists at Cold Spring Harbor Laboratory (CSHL) have obtained a precise molecular map of the binding site for an allosteric inhibitor in a subtype of the NMDA (N-methyl-D-aspartate) receptor, which is commonly expressed in brain cells.

17 Jun 2011

Scientists reveal complex protein mechanism that regulates genes linked with cancer

Scientists at Memorial Sloan-Kettering Cancer Center in New York and at IRB Barcelona reveal the mechanism of action of a protein that is essential for life and is associated with disease.

17 Jun 2011

VIVUS Avanafil phase 3 trial on erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that the positive results from REVIVE-RP, a phase 3 clinical trial evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED),will be presented this afternoon at the 2011 Cancer Survivorship and Sexual Health Symposium in Washington D.C.

17 Jun 2011

CBAI acquires assets of NeoCells for $320,000

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, is pleased to announce that it has acquired the assets of NeoCells, a subsidiary of ViviCells International, Inc., Evanston, Illinois, through a foreclosure procedure at a purchase price of $320,000.

17 Jun 2011

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.

17 Jun 2011

Innovative adult stem cell approach could help eliminate obesity

Innovative adult stem cell research by scientists at The University of Texas Health Science Center at Houston could aid efforts to apply the brakes to stem cells that produce the type of fat ringing the waists of millions. Research appeared today online ahead of the print issue of Cell Stem Cell.

17 Jun 2011

Roche RTCA HT Instrument allows fully-automated impedance screens for GPCRs

Label-free technologies have entered the stage of cellular drug discovery and high-throughput screening (HTS). For the measurement of G protein-coupled receptor (GPCR) activation electrical impedance represents an excellent universal readout technology, since different signaling pathways can be measured in one assay format using recombinant as well as primary cells.

17 Jun 2011

Medical societies urge diabetes patients to remain on their prescribed medications

Diabetes leaders today are responding to the announcement made by the U.S. Food and Drug Administration (FDA) yesterday that the use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.

17 Jun 2011

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Celgene International Sàrl announced that clinical data from two studies evaluating the use of REVLIMID® (lenalidomide) with standard R-CHOP chemotherapy in patients with untreated diffuse large B cell (DLBCL) or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

17 Jun 2011

Nuvilex describes advantages of cell encapsulation technology for multiple cancer therapies

Nuvilex, Inc. described today potential advantages of cell encapsulation technology for use in cancer therapies when more than one cancer-fighting drug is used.

17 Jun 2011

Obese, overweight and still healthy

It's become an axiom of health that overweight and obese people are not as healthy as their normal weight counterparts. In fact, obesity has been targeted as one of the country's most serious public health problems, with predictions of widespread heart disease, diabetes and cancer among the growing number of Americans who are overweight.

17 Jun 2011

'Blue baby' study sheds light on basic biology

A newborn described as a "happy blue baby" because of her bluish skin color but healthy appearance made a small mark in medical history when one of her physicians discovered something new in her genes-the hemoglobin Toms River mutation.

17 Jun 2011

Cancer News and Research

Latest Cancer News and Research

Endocrine Society honors BUSM professor with The Delbert A. Fisher Research Scholar Award

Tobacco promotion banned in Queensland stores

Adolescent obese males at risk of cancer later in life: Study

Cancer vaccine shows promise

RHEI receives Chinese SFDA acceptance letter for MuGard

Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital

NASDAQ halts Regeneron's common stock

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Precisely mapped allosteric binding site will facilitate design of drugs with minimal side effects

Scientists reveal complex protein mechanism that regulates genes linked with cancer

VIVUS Avanafil phase 3 trial on erectile dysfunction meets primary endpoints

CBAI acquires assets of NeoCells for $320,000

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Innovative adult stem cell approach could help eliminate obesity

Roche RTCA HT Instrument allows fully-automated impedance screens for GPCRs

Medical societies urge diabetes patients to remain on their prescribed medications

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Nuvilex describes advantages of cell encapsulation technology for multiple cancer therapies

Obese, overweight and still healthy

'Blue baby' study sheds light on basic biology

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in